We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
- Authors
Lee, J.-H.; Lim, S.-N.; Kim, D.-Y.; Kim, S. H.; Lee, Y.-S.; Kang, Y.-A.; Kang, S.-I.; Jeon, M. J.; Seol, M.; Seo, E.-J.; Chi, H. S.; Park, C. J.; Jang, S.; Yun, S.-C.; Lee, K.-H.
- Abstract
We analyzed the clinical significance of pre-transplant International Prognostic Scoring System (IPSS) score and comorbidity in 68 patients who underwent allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) (n=48) or acute myeloid leukemia evolved from MDS (n=20) between December 1995 and January 2008 in a single institute. During a median follow-up period of 41.0 months (range, 3.2–132.0 months), 27 patients died, and 7 relapsed. The 5-year probabilities of overall survival (OS) and event-free survival (EFS) were 60.0 and 57.4%, respectively, and the 5-year cumulative incidences of non-relapse mortality (CINRM) and relapse were 32.7 and 9.9%, respectively. OS, EFS, and CINRM were significantly different according to pre-transplant IPSS score and presence of pre-transplant comorbidity, which were independent risk factors along with Karnofsky performance score in multivariate analyses. In conclusion, pre-transplant IPSS score and comorbidity may stratify the risk of post transplant outcomes in MDS.
- Subjects
HEMATOPOIETIC stem cell transplantation; ACUTE myeloid leukemia; COMORBIDITY; CELL transplantation; MYELODYSPLASTIC syndromes
- Publication
Bone Marrow Transplantation, 2010, Vol 45, Issue 3, p450
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2009.190